**Education and Professional Experience:** 1. 2021/12-Present: The First Affiliated Hospital, Sun Yat-sen University, Associate Chief Physician 2. 2018/12-2021/12: The First Affiliated Hospital, Sun Yat-sen University, Attending Physician 3. 2015/07-2018/12: The First Affiliated Hospital, Sun Yat-sen University, Resident Physician 4. 2014/05-2015/04: Cedars-Sinai Medical Center, University of California, School of Medicine, LA, USA. (Joint PhD Training) 5. 2013/10-2014/05: Huntsman Cancer Institute, University of Utah, USA. (Joint PhD Training) 6. 2012/09-2015/06: The First Affiliated Hospital, Sun Yat-sen University, Ph.D. 7. 2009/09-2012/06: The First Affiliated Hospital, Sun Yat-sen University, Master's Degree 8. 2004/09-2009/06: Wuhan University, Department of Clinical Medicine, Bachelor's Degree **Publications:** (1) Hongyi Li#, Jian Tu#, Zhiqiang Zhao#, Lijuan Chen, Yueting Qu, Hongbo Li, Hao Yao, Xiaoshuai Wang, Dung-Fang Lee, Jingnan Shen, Lili Wen, Gang Huang#, Xianbiao Xie#. Molecular signatures of BRCAness analysis identifies PARP inhibitor Niraparib as a novel targeted therapeutic strategy for soft tissue Sarcomas. Theranostics. 2020; 10(21): 9477–9494. (2) Zhiqiang Zhao#, Qinglin Jin#, Xianbiao Xie, Yongqian Wang, Tiao Lin, Junqiang Yin, Gang Huang, Changye Zou*, Jingnan Shen*. Plastic lengthening amputation with vascularized bone grafts in children with bone sarcoma: a preliminary report. World Journal of Surgical Oncology. volume 18, Article number: 246 (2020) (IF: 2.754) 2020 Sep 15;18(1):246. (3) Zhiqiang Zhao#, Mansi Wu#, Xuelin Zhang#, Qinglin Jin, Yongqian Wang, Changye Zou, Gang Huang, Junqiang Yin, Xianbiao Xie*, Jingnan Shen*. CB-5083, an inhibitor of P97, suppresses osteosarcoma growth and stem cell properties by altering protein homeostasis. Am J Transl Res 2020;12(6):2956-2967 (4) Jiajun Zhang#, Weihai Liu#, Changye Zou#, Zhiqiang Zhao#, Yuanying Lai, Zhi Shi, Xianbiao Xie, Gang Huang, Yongqian Wang, Xuelin Zhang, Zepei Fan, Qiao Su, Junqiang Yin*, Jingnan Shen*, Targeting super-enhancer-associated oncogenes in osteosarcoma with THZ2, a covalent CDK7 inhibitor. Clin Cancer Res. 2020 Jun 1;26(11):2681-2692. (5) Changye Zou#, Zhiqiang Zhao#, Tiao Lin, Yongfu Huang, Xianbiao Xie, Junqiang Yin, Gang Huang, Bo Wang*, Jingnan Shen*. Long-term outcomes of limb salvage treatment with custom-made extendible endoprosthesis for bone sarcoma around the knee in children. J Orthop Surg Res. 2020 Jan 16;15(1):14. doi: 10.1186/s13018-019-1534-x. (6) Demeng Chen#, Zhiqiang Zhao#, Zixin Huang, Du-Chu Chen, Xin-Xin Zhu, Yi-Ze Wang, Ya-Wei Yan, Shaojun Tang, Subha Madhavan, Weiyi Ni, Zhan-peng Huang, Wen Li, Weidong Ji, Huangxuan Shen, Shuibin Lin*, Yi-zhou Jiang*, Super enhancer inhibitors suppress MYC driven transcriptional amplification and tumor progression in osteosarcoma. Bone Research (2018) 6:11 (7) Zhao Z#, Jia Q#, Wu MS#, Xie X, Wang Y, Song G, Zou CY, Tang Q, Lu J, Huang G, Wang J, Lin DC, Koeffler HP, Yin JQ*, Shen J*. Degalactotigonin, a natural compound from Solanum nigrum L., inhibits growth and metastasis of osteosarcoma through GSK3β inactivation-mediated repression of the Hedgehog/Gli1 pathway. Clin Cancer Res. 2018 Jan 1;24(1):130-144. (8) Weihai Liu#, Zhiqiang Zhao#, Yongqian Wang#, Wuguo Li, Qiao Su, Qiang Jia, Jiajun Zhang, Xuelin Zhang, Jingnan Shen* and Junqiang Yin*. Dioscin inhibits stem-cell-like properties and tumor growth of osteosarcoma through Akt/GSK3/β-catenin signaling pathway. Cell Death & Disease, 2018. 9(3): p. 343.